RESULTS:
Hemostatic profiles of pathogen-inactivated buffy coat platelet concentrate and plasma indicated decreased activity compared with their respective controls. Reconstitution of hemodiluted blood (hematocrit 5 20%) with packages that contained treated or nontreated components resulted in increased alpha and maximum clot firmness and enhanced clot-formation time. Simulating transfusion scenarios based on 30% blood replacement with a transfusion trauma package resulted in a nonsignificant difference in rotational thromboelastometry parameters between packages containing treated and nontreated blood components (p 0.05). Effects of pathogen inactivation treatment were evident when the trauma package percentage was 50% or greater and contained both pathogen inactivation-treated plasma and buffy coat platelet concentrate.
CONCLUSION: Rotational thromboelastometry
investigations suggest that there is relatively little impact of pathogen inactivation treatment on whole blood clot formation unless large amounts of treated components are used. O ver five million deaths occur each year worldwide as a result of bleeding in traumatic injuries. [1] [2] [3] Damage control resuscitation using a trauma transfusion package is crucial to rescue those patients with severe blood loss. Trauma transfusion packages are a rapid hemorrhage control consisting of the common transfusion components, red blood cells (RBCs), plasma, and platelets (PLTs), constituted at a biologic ratio of 1:1:1 for the treatment of coagulopathy, acidosis, hypothermia, and endothelial permeability 4 to increase hemostasis and decrease hemorrhage-related deaths in patients during the first 24 hours after treatment. [5] [6] [7] ABBREVIATIONS: BCPC 5 buffy coat platelet concentrate;
CFT 5 clot-forming time; MCF 5 maximum clot formation;
PIT 5 pathogen inactivation technology; ROTEM 5 rotational thromboelastometry.
One important development in blood banking is the introduction of pathogen inactivation (PI) technologies (PITs) which are designed to mitigate transfusion transmitted infections. [8] [9] [10] PITs are currently on the market or in late stage development for use with whole blood, RBC concentrates, PLT concentrates, or plasma. Several randomized clinical trials and hemovigilance data have confirmed the inactivation efficacy of PITs on viruses, bacteria, protozoa, and white blood cells. 11 One of these systems, the Mirasol technology (TerumoBCT), uses riboflavin (vitamin B 2 ) to modify nucleic acids upon their exposure to ultraviolet (UV) light; it prevents the replication of pathogens and leukocytes by modifying guanine residues through direct electron-transfer oxidative damage.
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Despite improving transfusion safety for transmission of infectious agents, studies of PI have indicated that there is an associated acceleration of the development of PLT storage lesions in treated PLT concentrates (PCs), 13, 14 and decreased plasma protein activity in PI-treated plasma units. 15 A recent study showed only a minimum impact of PI treatment on PLT aggregation and the hemostatic functionality of buffy coat PLT concentrate (BCPC) in additive solution upon Mirasol treatment. 16 Comparing the safety versus efficacy of PI-treated products, in a recent review, Hess and colleagues 17 used predictive mathematical modeling from published reports to calculate a risk of 400 extra trauma deaths annually attributed to the loss of potency of PI-treated PC and plasma. They showed that reduction in blood component potency (30% of PLT potency and 20% of effective coagulation activity) caused by the use of PI could lead to a net loss of life. We were interested in determining whether these mathematical models could be experimentally tested. Although the importance of proper monitoring and validation of new technologies is well understood, 18 we lack simple tools to predict transfusion outcome. There is poor correlation between common in vitro quality parameters and PLT recovery and survival. 19, 20 Recently, new approaches that seek to include most of the elements of hemostasis have appeared. Thromboelastography and, more recently, rotational thromboelastometry (ROTEM) have been used as viscoelastic technologies to measure fibrin polymerization as a reflection of hemostatic functionality of blood in vivo at 378C. 21 Although most commonly applied to the guidance of blood product use in surgical patients, 22, 23 thromboelastometry and ROTEM have also been adapted to test blood product function, 24 including PC during storage. 25, 26 This study aimed to determine whether ROTEM could be used to test mathematical models of the impact of PI treatment on transfusion efficacy. We initially sought to establish whether ROTEM could detect the effect on BCPC of riboflavin/UV light (Mirasol) on the hemostatic potential of BCPC produced in plasma and subsequent reconstitution with fresh-frozen plasma. We then investigated the impact of including PI-treated plasma or PLTs in a typical trauma transfusion package of RBCs, plasma, and BCPC at a ratio of 1:1:1. Finally, to model actual transfusion use, we investigated the impact of the dilution of the transfusion trauma package with untreated fresh blood at various hematocrits on its hemostatic function.
MATERIALS AND METHODS

Blood component collection and preparation
This study was approved by the Research Ethics Board of Canadian Blood Services (CBS), and healthy volunteers gave informed consent. Donors were asked about medication use in the days prior to donation, including use of aspirin or nonsteroidal anti-inflammatory drugs. Whole blood was collected at the CBS netCAD facility in Vancouver, and all units were held overnight on cooling plates for a minimum of 18 hours. BCPC was prepared from whole blood donations using the buffy coat production method, as previously described, 27 and were stored at 20 to 248C on a PLT shaker (Thermo Forma; Thermo Scientific). In addition, plasma units and packed RBCs were produced from the whole blood units and were stored at 48C for up to 5 days. For some experiments, PLT-poor plasma (PPP) was obtained from either the BCPC or the plasma units by centrifugation at 18,000 3 g for 40 minutes at 228C. This PPP was used to evaluate the effect of Mirasol treatment on the coagulation profile in the absence of detectable PLTs. Hemodiluted blood derived from whole blood of healthy donors was collected in citrated Vacutainer tubes (Becton Dickinson) directly before running the experiment and was prepared by decreasing the hematocrit concentration to 20%, a level chosen to reflect a realistic clinical situation of severe hemorrhage, by dilution with 0.9% saline solution, pH 5.5 (Baxter Corporation).
Pathogen reduction of BCPC and plasma
BCPCs produced in plasma and plasma units were illuminated according to the manufacturer's instructions. PI was achieved with riboflavin and UV light (Mirasol system) in which 35 mL of riboflavin solution (500 mmol/L) was added to the BCPC or plasma units before PI treatment. For studies that assessed the direct effect of Mirasol on BCPC, a pooled and split design was used in which one product was treated and the other BCPC was loaded with 35 mL saline and retained as a paired control. For all other studies, BCPC and plasma, either treated or untreated, were not derived from pooled samples but were used as individual donations to mimic transfusion scenarios.
BCPC sampling and preparation for hemostatic functionality (Advia 120; Siemens). For testing the functionality of an individual BCPC, aliquots of Group AB frozen plasma stored at 2808C were thawed at 378C and used to dilute the BCPC for testing, as previously described.
BCPC samples were reconstituted with fresh-frozen plasma to a PLT count of 100 3 10 9 /L and were tested on Days 2 (i.e., 5 the day after illumination, which was on Day 1), 5, 7, and 9 of the storage period. Eight independent experiments were conducted.
The preparation of transfusion packages after illumination
Transfusion packages were prepared using ABO-matched packed RBCs, plasma, and BCPC.
The reconstitution was at a ratio of 1 RBC unit:1 plasma unit:1 BCPC unit, where a BCPC unit is composed of the PLTs from buffy coats of four whole blood donations, and the RBC and plasma units are prepared from a whole blood donation. After the illumination process was completed on Day 1, the packages were combined as follows: 1) a control package containing untreated RBCs, plasma, and BCPC; 2) a package containing PI-treated BCPC units but untreated RBCs and plasma; 3) a package containing PI-treated plasma units but untreated RBCs and BCPC; and 4) a package containing both PI-treated BCPC and plasma units but untreated RBCs (Fig. 1) .
The replacement of the hemodiluted blood with Packages 1 or 4 (the control package or the package containing both treated components) was performed in vitro to mimic the transfusion scenario in vivo and was performed with different degrees of reconstitution: 30% blood replacement (70% hemodiluted whole blood 1 30% transfusion package; "hematocrit [HCT] 27.5%"), 50% blood replacement (50% hemodiluted whole blood 1 50% transfusion package; "HCT 33.5%"), and 70% blood replacement (30% hemodiluted whole blood 1 70% transfusion package; "HCT 37.5%") were reconstituted. Eight independent experiments of the entire series were conducted.
Hemostatic profile generation by ROTEM
ROTEM (Tem International GmbH) was used to determine the hemostatic profile of the different blood components. Simulated trauma transfusion packages were combined before loading them into the ROTEM cup. Each sample was incubated in a water bath at 378C to mimic physiological conditions in the human blood, and the mechanical and electronic calibration of each ROTEM channel was checked before each study according to the manufacturer's recommendations. A volume of 30 mL of 0.2 M CaCl 2 was added to re-calcify the samples loaded into each ROTEM cup. Kaolin was used to initiate the contact activation pathway of coagulation as recommended by the manufacturer. Recombinant human tissue plasminogen activator (wild-type tPA) (Aniara Diagnostica) was used at a final concentration of 2.5 nM to initiate fibrinolysis when indicated. Key parameters of the ROTEM profile, shown in Fig. 2 , are the clotting time (CT), which is the time to reach 2-mm amplitude from the beginning of the test; the clot-forming time (CFT), which is the time to reach 20-mm amplitude from a 2-mm amplitude; alpha, which is the rate of fibrin-PLT interaction; and the maximum clot formation (MCF), which is the maximum amplitude reached (in mm). MCF reflects the ability of PLTs and fibrinogen to produce the maximum clot quality and is influenced by Factor XIII and fibrinolysis.
PLT in vitro quality analysis
In parallel to the ROTEM analyses, the pH of the sampled BCPCs was measured within 2 hours of sampling (Orion 8115BNUWP ROSS Ultra Electrode; Thermo Fisher Scientific, Inc.), and PLT responsiveness was assessed by staining with fluorescent antibody (anti-CD62P-phycoerythrin; Beckman Coulter), as previously described. 28, 29 The response of PLTs to 10 mM adenosine diphosphate (ADP) was determined and is reported as the delta between PLTs that were positive for CD62P with and without exposure to 10 mM ADP. Six independent experiments (n 5 6) were performed.
Statistical analysis
First, normality of distribution of the data was tested using GraphPad 6 Prism software (GraphPad Software, Inc.).
When not normally distributed, the Johnson transformation was applied. A statistical analysis was performed using a two-way analysis of variance to determine differences between pathogen-reduced BCPC and control BCPC during storage time and transfusion packages that contained combinations of pathogen-reduced components, then finally comparing whole blood, hemodiluted blood, and its replacement with different ratios of transfusion packages. In case the Johnson transformation was not possible, nonparametric analyses were carried out using the Kruskal-Wallis test at different PLT counts during storage time for BCPC reconstitution to compare the different transfusion packages before and after their dilution with hemodiluted blood. Sample size calculations assumed a power of 80%, and a p value less than 0.05 to detect a potential difference in the in vitro quality variables. Data are reported as means and one standard deviation (61 SD). The Bonferroni correction was used to adjust the p value to account for multiple comparisons.
RESULTS
In vitro tests of treated BCPC
The pH value (Fig. 3a) changed significantly in both groups during storage, revealing a significant drop in the pathogen-reduced BCPC compared with the control BCPC (p < 0.01). The pH value fell below 6.8 in pathogenreduced BCPC by Day 9. The degree of PLT activation was significantly different between the pathogen-reduced BCPC and the control and increased significantly during the storage time (p < 0.01). The addition of ADP to a final concentration of 10 mM resulted in a significant increase in PLT activation level, reported as CD62P surface expression (Fig. 3b) ; however, the overall response to ADP decreased significantly with storage. The response to ADP was reduced for treated BCPC in plasma compared with control BCPC.
Hemostatic analysis of treated BCPC with ROTEM
The illumination of BCPC did not result in any significant difference in either CT or CFT compared with the untreated samples (Fig. 4A,B) . After Day 7, a significant decrease in the rate of the fibrin-PLT interaction was observed, as expressed by the alpha value in the pathogen-reduced BCPC (Fig. 4C) . MCF was significantly reduced in the pathogen-reduced BCPC compared with the control BCPC at all storage days tested (p 0.01) (Fig. 4D ). The fibrinolysis resistance was slightly decreased in the pathogen-reduced BCPC and was significant after 7 days of storage (p < 0.05) (Fig. 4E) . However, there was no significant correlation between the ROTEM profile of the Mirasol-treated BCPC and the in vitro tests (data not shown).
Impact of PI on plasma
PI treatment resulted in significant delay in the time for the clot to increase (CFT) from 2 to 20 mm in PPP isolated from BCPC units or plasma units (p < 0.01), with an approximately five-fold increase in the plasma CFT and three-fold increase in the CFT with treated BCPC. Furthermore, both the rate of fibrin-PLT interaction (alpha) and maximum clot firmness dropped significantly in the treated BCPC and plasma units compared with their respective controls (p < 0.05) (Fig. 5) .
Modeling the use of transfusion packages in the treatment of trauma
The control samples were collected from whole blood of healthy donors and hemodiluted with 0.9% normal saline to a hematocrit of 20%. The replacement of hemodiluted blood in the test mix with the transfusion packages was at different ratios to create 30%, 50%, and 70% blood replacement. The transfusion packages with or without pathogen-reduced components were tested separately (Fig. 6 ). As expected, hemodiluted blood had a significantly altered ROTEM profile, consistent with hypocoagulability, which provided a model system in which to test the transfusion packages for their ability to return the profile to that of fresh whole blood. 30 ROTEM traces of the transfusion package that had treated components were negatively impacted compared with the control transfusion package, as demonstrated by a the reduction in the overall readout (p < 0.01). The CFT was 179.4 6 42.9 versus 130.1 6 27.4 seconds, the rate of PLT-fibrin interaction was 65.4 6 4.6 versus 56.5 6 6.0, and MCF was 56.2 6 2.5 versus 50 6 2.5 mm (Fig. 6A-C) . Transfusion packages that contained either pathogen-reduced plasma or pathogenreduced BCPC had similar hemostatic profiles, with a CFTs of 153.2 6 29.2 and 160 6 20.1 seconds, respectively, and an MCF of 52.2 6 2.2 mm and 51.8 6 2.6 mm, respectively; however, their rates of fibrin-PLT interaction (62.5 6 2.1 and 62.8 6 1.8, respectively) were superior to the rates in the transfusion packages that contained both pathogen-reduced plasma and pathogen-reduced BCPC (58.5 6 5.8; p < 0.05). To model the worst-case scenario for currently licensed PITs, we used both treated PLTs and plasma in subsequent experiments. Replacing the hemodiluted blood with the transfusion packages at 30%, 50%, or 70% resulted in increased alpha and MCF and shortened CFT. Although the ROTEM profile of 30% blood replacement was significantly different from the whole blood ROTEM profile, the overall effect of treatment was less severe than that seen with higher transfusion package ratios (p 0.05) (Fig. 6) .
DISCUSSION
This study investigated the ability of trauma transfusion packages consisting of pathogen-reduced or untreated blood components to correct the hemostatic profile using ROTEM in an in vitro model of transfusion in trauma patients. Our data support the concept that the use of blood products treated with PITs may reduce transfusion efficacy for patients undergoing massive transfusion. 17 However, this risk is related to the combinations of products used and the amount of blood volume replaced. Our studies have focused on the Mirasol PIT as applied to PCs or plasma. We observed that Mirasol treatment lowered the hemostatic profile of PI-treated BCPC but that the product may still be efficacious for transfusion, as suggested by clinical assessments of these products.
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Although shear-stress-independent, in vitro tests showed a higher degree of deterioration of PLTs after treatment, the ROTEM profile indicated that Mirasol-treated BCPC units did not show an effect until Day 7 of storage. The dramatic decrease in the alpha parameter of the pathogen-reduced BCPC units after Day 7 might have been caused by the decrease in the residual coagulation factor activity, notably fibrinogen, which is a significant contributor to the alpha parameter and is known to be affected by Mirasol treatment 33 along with other coagulation factors, such as Factor VIII. 34 Impaired PLT function also may contribute to the modified clot signature, because intentional impairment of PLT function has been shown to impact the ability to detect fibrinogen activity at the expected level. 35 Another possibility is that some level of conversion of fibrinogen to fibrin during the treatment was associated with altered ROTEM measurements, as has been reported for the inhibition of some coagulation factors in other settings. 36 An increase in fibrinolysis of the pathogen-reduced BCPC observed at the end of the storage period may have resulted from an imbalance between tPA and the plasminogen-activating inhibitors (PAI-1) present in the blood with the trauma transfusion package from treated or nontreated plasma and PLTs, respectively. The replacement was at three different concentrations: 30% blood replacement (70% hemodiluted whole blood 1 30% transfusion package; "Hct 27.5%"), 50% blood replacement (50% hemodiluted whole blood 1 50% transfusion package; "HCT 33.5%"), and 70% blood replacement (30% hemodiluted whole blood 1 70% transfusion package; "HCT 37.5%"). The hemostatic functionality of the transfusion package alone is indicated by (᭛) for the control package and (᭜) for the package containing treated plasma and PLTs. (*) Significant difference between the two study arms (p < 0.01). Results are displayed as means of eight replicates 6 SD.
PLTs. tPA should be neutralized by a certain concentration of PAI-1 from the PLTs. Thus, if the final concentration of tPA had been higher than that of the PAI-1, then more fibrinolysis would have occurred; and the converse would yield a lower degree of fibrinolysis. This would imply that the activity or level of the PAI-1 had already decreased after illumination, resulting in a greater amount of fibrinolysis. Notably, a significant increase in fibrinolysis was not observed until Day 9, well after the normal 5-day or 7-day allowable storage period. 37, 38 Hemostatic profiles of Mirasol-treated BCPC as well as PPP derived from plasma or BCPC units indicated decreased activity compared with their respective controls. However, PPP from BCPC was less affected than PPP from plasma units. This result might be attributed to a protective effect provided by the cellular components in the units whereby the coagulation proteins receive less direct damage from the UV dose. 39, 40 Numerous studies have demonstrated the impact of illumination on the in vitro quality parameters of plasma and BCPC. Although clinical trials of both licensed PITs demonstrated variable reductions in corrected count increments and time between transfusions, neither these changes nor the aforementioned in vitro quality changes translated into increased adverse events. [41] [42] [43] However, because few studies have been conducted with multiple types of treated products in patients with severe hemorrhage, it is important to determine the impact of the PI on the quality of the transfusion packages used in massive transfusion protocols. In this study, we have attempted to mimic the in vivo state as closely as possible by performing the replacement of RBCs, plasma, and PLTs to hemodiluted blood with the transfusion packages as prepared for massive transfusion protocols. Hemodiluted blood shows a prolonged CFT with a lesser degree of MCF at an earlier stage than that observed in standard laboratory-based monitoring. 44 This behavior results from a massive loss of endogenous inhibitors of fibrinolysis. 45, 46 Therefore, we chose healthy donors and diluted their blood samples with normal saline to simulate hemorrhage occurring in trauma patients who have been treated for fluid loss but have not yet received transfusion with cellular components or plasma and are left with a 50% loss of RBC mass. However, we did not decrease the hematocrit level to less than 20%, as may be seen with high mortality trauma. The assessment of these simulated transfusions by ROTEM demonstrated that the parameters measured in the clot signature were affected by the use of Mirasoltreated products in this model. The ratio of hemodiluted blood to the transfusion packages affected the CFT, alpha value, and MCF of the clot signature. The addition of Mirasol treatment significantly reduced the efficacy in the two groups with the highest proportion of transfusion packages: 50% and 70% blood replacement. No difference was observed when the treated transfusion packages were used to supplement at 30% of the blood volume. Although direct translation to human transfusion can only be generalized, the 50% replacement model approximates a fourunit RBC transfusion, a quantity that, at least in cardiac surgery, has not been associated with an increase in mortality. 47 The 70% replacement model approximates situations of massive transfusion in which there is already a high mortality rate. In this setting, these studies suggest that hemostasis would be further compromised by the use of PI-treated PLTs and plasma, in support of concerns raised by others. 17 As with all models, our study has its limitations. ROTEM lacks the involvement of the endothelium and thus is an imperfect way to measure hemostasis. Whether these ROTEM results are predictive of clinical use of pathogen-reduced blood products remains to be determined by clinical trials. The study reported here suggests that, if ROTEM represents a closer assessment of in vivo hemostasis than other typical in vitro assays performed on single components, then the effects of pathogen reduction technology may be slightly less than suggested by mathematical modeling. 17 Importantly, we did not see a complete failure to form a clot even at the highest volumes of treated products tested. Nevertheless, the use of multiple pathogen-reduced components in transfusion packages used for massive transfusion protocols should be undertaken with caution and with consideration of the use of other means to promote hemostasis. The ongoing determination of the balance between increased blood safety from pathogen transmission and decreased efficacy arising from the treatment itself remains an important consideration.
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